PRospective evaluation of the European Society of Cardiology 0/1h-algorithm`s safety and efficacy for triage of patients with suspected myocardial infarction (PRESC1SE-MI): Rationale and design of a prospective international multicenter stepped-wedge cluster randomized controlled trial
- PMID: 41177204
- DOI: 10.1016/j.ahj.2025.107299
PRospective evaluation of the European Society of Cardiology 0/1h-algorithm`s safety and efficacy for triage of patients with suspected myocardial infarction (PRESC1SE-MI): Rationale and design of a prospective international multicenter stepped-wedge cluster randomized controlled trial
Abstract
Background: International practice guidelines recommend the more rapid European Society of Cardiology (ESC) 0/1h-algorithm for the triage of patients with suspected myocardial infarction (MI) as the preferred option and consider the ESC 0/3h-algorithm as an alternative. However, many centers worldwide have not yet adopted the ESC 0/1h-algorithm in clinical practice due to uncertainty which approach best balances safety and efficacy.
Methods: PRESC1SE-MI (PRospective Evaluation of the European Society of Cardiology 0/1h-algorithm`s Safety and Efficacy for Triage of Patients with Suspected Myocardial Infarction) is an international, investigator-initiated multicenter, stepped-wedge, cluster randomized controlled trial. At least 52,156 consecutive adult patients with nontraumatic acute chest discomfort and suspected MI presenting to the Emergency Department (ED) will be enrolled. Sites still using the ESC 0/3h-algorithm as standard-of-care will be randomized to implement the more rapid ESC 0/1h-algorithm at an early or late implementation step. During the validation phase, participating sites continue to use the ESC 0/3h-algorithm. The co-primary outcomes are a composite of type 1 MI or all-cause death at 30 days (safety), and the length of stay in the ED (efficacy). The trial is designed to show noninferiority for safety and superiority for efficacy, with a power of at least 90%.
Conclusions: PRESC1SE-MI is the largest international multicenter trial to date evaluating the safety and the efficacy of the implementation of the more rapid ESC 0/1h-algorithm at late adopting centers across multiple countries and healthcare systems. Its findings have the potential to improve patient care and reduce healthcare costs.
Trial registration: https://clinicaltrials.gov/study/NCT05649384.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest Drs. Boeddinghaus and Mueller designed the study, wrote the paper, and decided to publish the trial design. All authors have read and approved the manuscript. The sponsors had no role in designing or conducting the study and have no role in gathering or analyzing the data. The manuscript and its contents have not been published previously and are not being considered for publications elsewhere in whole or in part in any language, including publicly accessible web sites or e-print servers. We disclose that Dr. Boeddinghaus is supported by an Edinburgh Doctoral College Scholarship and research grants from the University of Basel, the University Hospital of Basel, the Division of Internal Medicine, the Swiss Academy of Medical Sciences, the Gottfried and Julia Bangerter-Rhyner Foundation, the Swiss National Science Foundation, the Swiss Heart Foundation, and has received honoraria from Siemens, Roche Diagnostics, Ortho Clinical Diagnostics, Quidel Corporation, and Beckman Coulter, and travel support from Medtronic and Vascularmedical, all outside the submitted work. Dr. Bima received a grant from the Swiss Heart Foundation (FF23062) and receives consulting fees from Scandinavian CRO (SCRO, part of Aurevia), all outside the submitted work. Outside of this study, Dr. Bueno receives research funding from the European Union (EU4H-2022-JA-03), Instituto de Salud Carlos III, Spain (FORTALECE program, PI21/01572), Sociedad Española de Cardiología, AstraZeneca, Boehringer Ingelheim, and Janssen; and has received in the past consulting/speaking fees from Novo Nordisk and Organon. Enrico Lupia and Fulvio Morello are supported by the Fondazione Ricerca Molinette (grant 2023 to EL) and the Università degli Studi di Torino (MORF_RILO_21_02 and 23_03, to FM). Dr. Mueller has received research support from the Swiss National Science Foundation, the Swiss Heart Foundation, Innosuisse, the University of Basel, the University Hospital Basel, Abbott, Astra Zeneca, Beckman Coulter, Biomerieux, Boehringer Ingelheim, Idorsia, Novartis, Ortho Cinical Diagnostics, Quidel, Roche, Siemens, Singulex, SpinChip, Sphingotec, as well as speaker honoraria/consulting honoraria from Abbott, Acon, Amgen, Astra Zeneca, Boehringer Ingelheim, Bayer, BMS, Idorsia, Novartis, Osler, Roche, SpinChip, and Sanofi, outside of the submitted work. All other authors declare that they have no conflict of interest with this study.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical
